Bristol Myers' CAR-T Breyanzi busts out a win in earlier-line lymphoma, potentially cracking open an expanded market
Despite being third to the field in B cell lymphoma, Bristol Myers Squibb has repeatedly argued its CAR-T Breyanzi could have the juice to overtake …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
